NLS Pharmaceutics Unveils Promising Findings on Mazindol ER's Utility in Fentanyl Dependence at ASCP 2025 NLS Pharmaceutics reveals new preclinical insights on Mazindol ER's effectiveness against fentanyl addiction at the 2025 ASCP Annual Meeting, showcasing its dual action.

NLS Pharmaceutics Unveils Promising Findings on Mazindol ER's Utility in Fentanyl Dependence at ASCP 2025 #Switzerland #NLS_Pharmaceutics #Zurich #Mazindol_ER #fentanyl

NLS Pharmaceutics Unveils Innovative Research at 2025 ASCP Annual Meeting NLS Pharmaceutics has submitted three groundbreaking research abstracts for the 2025 ASCP Annual Meeting, focusing on CNS disorders and innovative therapies.

NLS Pharmaceutics Unveils Innovative Research at 2025 ASCP Annual Meeting #Switzerland #NLS_Pharmaceutics #Zurich #Mazindol_ER #AEX-41

NLS Pharmaceutics Unveils Preclinical Approach for Treating Fentanyl Dependence with Mazindol ER NLS Pharmaceutics has launched a preclinical program for Mazindol ER as a treatment for fentanyl dependence, addressing a significant public health crisis.

NLS Pharmaceutics Unveils Preclinical Approach for Treating Fentanyl Dependence with Mazindol ER #Switzerland #NLS_Pharmaceutics #Zurich #Mazindol_ER #Fentanyl_Dependence